Takuya Tsunoda

4.5k total citations
162 papers, 3.1k citations indexed

About

Takuya Tsunoda is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Takuya Tsunoda has authored 162 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Oncology, 58 papers in Immunology and 53 papers in Molecular Biology. Recurrent topics in Takuya Tsunoda's work include Immunotherapy and Immune Responses (48 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Immune Cell Function and Interaction (28 papers). Takuya Tsunoda is often cited by papers focused on Immunotherapy and Immune Responses (48 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Immune Cell Function and Interaction (28 papers). Takuya Tsunoda collaborates with scholars based in Japan, United States and Australia. Takuya Tsunoda's co-authors include Hideaki Tahara, Hiroki Yamaue, Yusuke Nakamura, Hiroshi Tanimura, Masaji Tani, Yataro Daigo, Satoshi Wada, Yutaro Kubota, Makoto Iwahashi and Yusuke Nakamura and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Takuya Tsunoda

155 papers receiving 3.0k citations

Peers

Takuya Tsunoda
Kenneth E. Hung United States
János L. Tanyi United States
Alexandria P. Cogdill United States
Yuliya Pylayeva‐Gupta United States
Els M.E. Verdegaal Netherlands
Sapna P. Patel United States
Marion Dorsch United States
Patricia Rayman United States
Chantale Bernatchez United States
Lindy G. Durrant United Kingdom
Kenneth E. Hung United States
Takuya Tsunoda
Citations per year, relative to Takuya Tsunoda Takuya Tsunoda (= 1×) peers Kenneth E. Hung

Countries citing papers authored by Takuya Tsunoda

Since Specialization
Citations

This map shows the geographic impact of Takuya Tsunoda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takuya Tsunoda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takuya Tsunoda more than expected).

Fields of papers citing papers by Takuya Tsunoda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takuya Tsunoda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takuya Tsunoda. The network helps show where Takuya Tsunoda may publish in the future.

Co-authorship network of co-authors of Takuya Tsunoda

This figure shows the co-authorship network connecting the top 25 collaborators of Takuya Tsunoda. A scholar is included among the top collaborators of Takuya Tsunoda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takuya Tsunoda. Takuya Tsunoda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kubota, Yutaro, Ming Zhao, Qinghong Han, et al.. (2025). Engineered Methioninase-expressing Tumor-targetingSalmonella typhimuriumA1-R Inhibits Syngeneic-Cancer Mouse Models by Depleting Tumor Methionine. Cancer Genomics & Proteomics. 22(2). 247–257. 1 indexed citations
2.
3.
Shimizu, Takashi, Eisuke Inoue, Ryotaro Ohkuma, et al.. (2023). Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis. Frontiers in Immunology. 14. 1308381–1308381. 6 indexed citations
4.
5.
Kubota, Yutaro, YUSUKE AOKI, NORIYUKI MASAKI, et al.. (2023). Methionine restriction of glioma does not induce MGMT and greatly improves temozolomide efficacy in an orthotopic nude-mouse model: A potential curable approach to a clinically-incurable disease. Biochemical and Biophysical Research Communications. 695. 149418–149418. 13 indexed citations
6.
Ieguchi, Katsuaki, Masabumi Funakoshi, Taishi Mishima, et al.. (2022). The Sympathetic Nervous System Contributes to the Establishment of Pre-Metastatic Pulmonary Microenvironments. International Journal of Molecular Sciences. 23(18). 10652–10652. 12 indexed citations
7.
Arai, Jun, Ken‐ichi Fujita, Kaku Goto, et al.. (2022). Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer. BMC Cancer. 22(1). 428–428. 5 indexed citations
8.
Ieguchi, Katsuaki, Takeshi Tomita, Toshifumi Takao, et al.. (2021). Analysis of ADAM12-Mediated Ephrin-A1 Cleavage and Its Biological Functions. International Journal of Molecular Sciences. 22(5). 2480–2480. 14 indexed citations
9.
Ohkuma, Ryotaro, Katsuaki Ieguchi, Makoto Watanabe, et al.. (2021). Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies. Biomedicines. 9(12). 1929–1929. 24 indexed citations
10.
Kikuchi, Tomohiro, Kosaku Mimura, Mai Ashizawa, et al.. (2019). Characterization of tumor-infiltrating immune cells in relation to microbiota in colorectal cancers. Cancer Immunology Immunotherapy. 69(1). 23–32. 31 indexed citations
11.
Takeda, Kazuyoshi, Kazutaka Kitaura, Ryuji Suzuki, et al.. (2018). Quantitative T-cell repertoire analysis of peripheral blood mononuclear cells from lung cancer patients following long-term cancer peptide vaccination. Cancer Immunology Immunotherapy. 67(6). 949–964. 11 indexed citations
12.
Tomita, Yusuke, Akira Yuno, Hirotake Tsukamoto, et al.. (2013). Identification of Promiscuous KIF20A Long Peptides Bearing Both CD4+ and CD8+ T-cell Epitopes: KIF20A-Specific CD4+ T-cell Immunity in Patients with Malignant Tumor. Clinical Cancer Research. 19(16). 4508–4520. 50 indexed citations
13.
Okamoto, Isamu, Tokuzo Arao, Masaki Miyazaki, et al.. (2012). Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors. Cancer Science. 103(12). 2135–2138. 13 indexed citations
14.
Hayashi, Hidetoshi, Takayasu Kurata, Yasuhito Fujisaka, et al.. (2012). Phase I trial of OTS11101, an anti‐angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor. Cancer Science. 104(1). 98–104. 16 indexed citations
15.
Miyazawa, Motoki, Takuya Tsunoda, Seiko Hirono, et al.. (2009). Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Science. 101(2). 433–439. 90 indexed citations
16.
Imai, Katsunori, Shinya Hirata, Atsushi Irie, et al.. (2008). Identification of a Novel Tumor-Associated Antigen, Cadherin 3/P-Cadherin, as a Possible Target for Immunotherapy of Pancreatic, Gastric, and Colorectal Cancers. Clinical Cancer Research. 14(20). 6487–6495. 90 indexed citations
17.
Ishizaki, Hidenobu, Takuya Tsunoda, Satoshi Wada, Masabumi Shibuya, & Hideaki Tahara. (2006). Development of anti-angiogenic cancer vaccine using epitope peptides derived from vascular endothelial growth factor receptor 1 (VEGFR1). Cancer Research. 66. 331–331. 1 indexed citations
18.
Tsunoda, Takuya, Hiroshi Tanimura, Tsukasa Hotta, et al.. (2000). In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer. Journal of Surgical Oncology. 73(1). 6–11. 12 indexed citations
19.
Terasawa, Hiroshi, Hiroshi Tanimura, Mikihito Nakamori, et al.. (1999). Antitumor Effects of Interleukin‐2 Gene‐modified Fibroblasts in an Orthotopic Colon Cancer Model. Japanese Journal of Cancer Research. 90(9). 1000–1006. 10 indexed citations
20.
Motojima, Koichi, et al.. (1992). [Evaluation of immunoreactivity to erbB-2 protein as a marker of prognosis in bile duct carcinoma].. PubMed. 93(9). 952–5. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kenneth E. Hung Breakdown of academic impact, for papers by János L. Tanyi Breakdown of academic impact, for papers by Alexandria P. Cogdill Breakdown of academic impact, for papers by Yuliya Pylayeva‐Gupta Breakdown of academic impact, for papers by Els M.E. Verdegaal Breakdown of academic impact, for papers by Sapna P. Patel Breakdown of academic impact, for papers by Marion Dorsch Breakdown of academic impact, for papers by Patricia Rayman Breakdown of academic impact, for papers by Chantale Bernatchez Breakdown of academic impact, for papers by Lindy G. Durrant
Rankless by CCL
2026